^
    3years
    AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. (PubMed, Physiol Rep)
    Remarkably, their in vivo antitumor effectiveness was not significantly enhanced by concomitant administration of a multi-target tyrosine kinase inhibitor. Bemcentinib and tilvestamab qualify as compounds of potentially high clinical interest in AXL overexpressing RCC.
    Preclinical • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • VIM (Vimentin) • GAS6 (Growth arrest specific 6)
    |
    AXL expression • AXL overexpression • VIM expression
    |
    bemcentinib (BGB324) • tilvestamab (BGB149)